# Libra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/libra-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.libratherapeutics.com
- Total disclosed funding: $29M
- Latest round: Series A (Sep 23, 2020)
- Investors on record: 6

## About

Libra Therapeutics focuses on developing therapeutics that enhance lysosomal function to combat neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, improving patient outcomes through innovative treatment options.Founded in 2019 and headquartered in San Diego, US, Libra Therapeutics specializes in innovative therapies targeting lysosomal function. The company raised USD 29.00 mn in Series A funding on September 23, 2020, with participation from investors including Boehringer Ingelheim Venture and Epidarex Capital. The CEO, Isaac Veinbergs, leads the company which has executed one deal to date and does not have subsidiaries or a parent company.Libra Therapeutics develops innovative therapeutics aimed at improving lysosomal function to combat neurodegeneration associated with diseases like amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Their core offerings focus on small molecule-targeted mechanisms that enhance the body's ability to degrade and eliminate toxic proteins and dysfunctional organelles, addressing the underlying dysfunction characterizing these conditions. The therapeutic candidates activate lysosomal channels such as TRPML1, promoting autophagy and lysosomal biogenesis, and primarily target patients suffering from neurodegenerative disorders in North America and Europe.Information regarding the revenue structure of Libra Therapeutics is not publicly available. The company operates a business-to-business (B2B) model, engaging in partnerships with pharmaceutical companies and academic institutions for drug development. Revenue generation may stem from milestones achieved in drug development and licensing agreements, although specific pricing plans or revenue figures for individual products are not provided in the available documentation.Libra Therapeutics intends to utilize the USD 29.00 mn raised in Series A funding to advance its therapeutic candidates and expand its market presence. The company is focused on launching new products that enhance lysosomal function, with plans to target additional markets in Europe and North America by the end of 2022. The recent funding will support research and clinical trials, facilitating the development of effective solutions for neurodegenerative diseases.

## Funding rounds

- Series A, Sep 23, 2020, $29M — Sante Ventures, Boehringer Ingelheim Venture, Epidarex Capital, Dolby Family Ventures, Yonjin Venture, Sixty Degree Capital

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series A
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series A